The second-line treatment of nasopharyngeal cancer by Junshi BioPD-1 of the Pharmaceutical Speed Reading Society has been approved in China

February 19, 2021 / Medical Information At a Glance: First Health Insurance Regulations Issued; Junshi BioPD-1 Second Line Treatment of Nasopharyngeal Cancer Approved in China; World's First Human Challenge Trial for New Coronavirus Approved ... Daily fresh medicine news, speed reading society and you pay attention to! Part1 Policy Brief CDE Issued New Guidelines On February 18, 2021, the official website of the Drug Review Center of the State Drug Administration issued the Guidelines for the Evaluation of Biosyspole Similarities and The Technical Guidelines for The Extratrollering of Adaptations (February 10, 2021 Written Time), effective February 18, 2021, on the date of publication, which provide technical references to industry, researchers and regulatory agencies for further standardizing and guiding the development and evaluation of biosyspoxic drugs.
(CPhl Pharmaceuticals Online) the first health care regulations issued: fraud will be fined 2 times the amount of fraud less than 5 times on February 19, the "Health Care Fund Use Supervision and Administration Regulations" issued today, will be implemented on May 1, 2021.
Regulations for the first time specify the obligations of insured persons, if an individual for the purpose of cheating insurance, the medical insurance certificate to others under false use, or repeated access to medical insurance treatment, etc., will suspend their medical expenses network settlement for 3 to 12 months, and the amount of fraud 2 times 5 times the fine.
, the regulations clearly require that the medical insurance fund is earmarked and that no organization or individual may appropriate or misappropriate it.
(Caixin) State Drug Administration disclosed the latest progress in the development of the new crown vaccine February 19, during the prevention and control of the new crown pneumonia epidemic, the State Drug Administration organized the outbreak prevention and control of drug-using equipment centralized treatment, and actively promote the new crown virus vaccine research and development and listing.
At present, a total of 22 drugs have been approved for treatment and prevention clinical trials of neo-coronary pneumonia and its related adaptations, 2 drugs have been approved with conditions, and 54 new coronavirus testing reagents have been approved, with a daily production capacity of 2.418 million copies.
all over the emergency approval of medical protective clothing registration certificate 420, medical protective mask registration certificate 307.
has conditionly approved the listing of two new coronavirus vaccines in China, and has approved a total of 16 vaccine varieties in 5 technical routes for clinical trials, of which 6 vaccine varieties have been conducted in Phase III clinical trials.
(Caixin) A pharmaceutical company was fined 50,000 yuan on February 18, Sichuan Drug Administration published an administrative penalty decision information, information shows that Sichuan Jingxin Pharmaceutical Tablets Co., Ltd. because of bone fracture supplements unqualified, was fined 50,000 yuan.
of the drug involved in the case was 24,692.72 yuan, and the proceeds from the sale were 18010.22 yuan;
(Sichuan Provincial Drug Administration) Part2 reached a $960 million RIPK1 inhibitor partnership with Lilly and Rigel on Thursday, lilly announced an exclusive licensing agreement with Rigel Pharmaceuticals, which will jointly develop Rigel's RIPK1 inhibitor R552 and will be responsible for the commercialization of the therapy for all adaptations, including autoimmune and inflammatory diseases.
addition to Lilly's $125 million upfront payment to Rigel, Rigel will also be eligible for a milestone payment of $835 million, as well as tiered royalties.
(Sina Pharmaceutical News) No double medical completed hundreds of millions of yuan B round financing artery network first learned that no double medical recently completed hundreds of millions of yuan B round financing.
The current round of financing by China Investment Ventures, Qiming Ventures joint venture capital, existing shareholders Northern Lights Ventures, Sugao New Ventures, Yuanyi Capital, etc. continue to invest, Dotstone Capital as the exclusive financial adviser.
this round of funds will be used to expand the size of the research and development team, promote clinical trials, expand product pipelines and so on.
(Arterial Network) first completed the 250 million yuan B round of financing for Da Bio on February 19, the first for Da Bio announced the recent completion of 250 million yuan B round of financing.
this round of financing led by Jifeng Capital, the original investors Junlian Capital, Haibang Investment continued to participate in this financing.
(Pharmaceutical Mission) Reig Pharmaceuticals completed a $90 million B round of financing on February 19, Reed Pharmaceuticals announced that the company had successfully completed a $90 million B round of financing in February 2021.
this round of financing led by Lilly Asia Fund, Zhengsing Valley Capital, Lanting Capital, Taifu Capital and Xiangfeng Investment jointly participated.
(Pharma Mission) Part3 drug "first-in-class" psoriasis topical therapy has significant long-term effects Today, Dermavant Sciences announced that the company developed tapinarof emulsion, in the treatment of plaque-like psoriasis adult patients in the medium-term analysis of the long-term open labeling study obtained positive results.
-term analysis showed that long-term use of tapinarof could further improve the patient's skin symptoms, and that even if the patient stopped taking the drug after the skin symptoms had disappeared, the therapeutic effect could continue for nearly four months.
(Xinhua) -- Five years later, 60 percent of patients are still in remission with the long-term efficacy of CAR-T therapy, according to a long-term study published in the New England Journal of Medicine, which showed positive results in long-term follow-up studies.
60% of patients with B-cell lymphoma treated with Kymriah are still in remission after 5 years of treatment.
(Pharmaceutical Mingkangde) Baiotai "Golimu monosuplic" biosynthic drug initiation Phase III clinical today, Insight database shows that Biotay's Golimu monobial-like drug BAT2506 was first publicized to launch the International Multi-Center Phase III clinical.
, BAT2506 is the only Golimu monobial-like drug entering the clinic.
(Insight database) the world's first new coronavirus human challenge test was approved by foreign media reported that the British government issued a statement on the 17th local time, the country's clinical trial ethics agency has approved a new coronavirus human trial, 90 adult volunteers exposed to the new coronavirus environment, this is the world's first approved new coronavirus "human challenge test."
(Medical Valley Network) Junshi bioPD-1 second-line treatment of nasopharyngeal cancer in China was approved on February 19, according to the NMPA drug approval issued notice, Junshi Bio's Ripley monoanti-anti-injection was approved by the new drug approval documents.
the acceptance number associated with the drug approval documents obtained this time is consistent with the acceptance number of last year's listing application for inclusion in the priority review, which means that Tripley monoantigen is officially approved in China for second-line treatment of recurrence/metastatic nasopharyngeal cancer.
(immediate drug news) Sanofi anti-allergy drug hydrochloric acid non-sofina tablets were approved in China today, NMPA issued drug approval documents to be received information shows that Sanofi anti-allergic drug hydrochloric acid non-sofina tablets of the three listing applications have been officially approved in China.
According to publicly available information, hydrochloric acid non-sofana tablets are an H1-subject antagonist, and the drug's approved adaptation may be allergic rhinitis and chronic idynamic urticaria.
(Drug Mingkangde) four-ring medicine "injection of type A botulinum toxin" new specifications were approved for listing on February 19, the State Drug Administration official website shows that the exclusive agent of four-ring medicine injection of type A botulinum toxin was approved, it is understood that this approval is Letybo 50U.
Injection of type A botulinum toxin is mainly used for eyelid spasms, facial muscle spasms, and associated dystuffic dystuffles, temporarily improving moderate to severe frown lines caused by frown muscle/or lowering muscle activity in adults 65 years of age and younger. (Insight Database) Hengrui Pharmaceuticals: Fluorine Pali capsules and apatinib tablets will be conducted in clinical trials in the near future On February 19, Hengrui Pharmaceuticals announced that it has recently received a "Notice of Approval for Clinical Trials of Drug Trials" for fluorine Pali capsules and apatini tablets of methafonate approved by NMPA, and will conduct clinical trials in the near future.
fluorine palladium capsules are used for the treatment of patients with platinum-sensitive relapsed ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have underwent second-line and above chemotherapy with embryo BRCA mutations;
(Hengrui Pharmaceutical Announcement) East Sunshine "Mendong Insulin 30" listing application was accepted domestic third recently, CDE official website shows that The East Sunshine Drug "Mendong Insulin 30" listing application has been undertaken, becoming the third domestic reported listing of Mendong Insulin 30 products.
, in addition to the original research products No. 30, only Ganli Pharmaceuticals was approved for listing in December 2020.
(Insight Database)